UNSPSC 51284123: Cefcapene pivoxil

This classification denotes a cephalosporin antibiotic C23H29N5O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8I8MJ56XFQ, chemically known as 2,2-dimethylpropanoyloxymethyl (6r,7r)-7-(((z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl)amino)-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, but more generally known as cefcapene pivoxil, which bears US NIH Compound Identifier 5282438.

UNSPSC 51284123 Cefcapene pivoxil is a Commodity code nominally designating a specific oral antibiotic product, but recent state and local solicitations tagged under this code show little alignment with the nominal scope. The four recent opportunities posted between January and June 2026 target broader categories of pharmaceutical and medical supply procurement — naloxone and drug deactivation systems, therapeutic pharmacy direct-to-manufacturer programs, emergency medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals distributed through wholesalers — rather than cefcapene pivoxil specifically. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal fire departments (City of Tampa), and state multistate cooperative purchasing alliances (Minnesota MMCAP). The code appears to function as a catch-all pharmaceutical or medical supply classifier in some jurisdictions' procurement systems rather than a precise product-level designator.

Recent activity spans Florida, Texas, Minnesota, and cooperatively across multiple states via MMCAP, with the largest contract by estimated value being the City of Tampa's medical and first aid supplies procurement (estimated at $700,000.00, IFB 26P00145, due March 13, 2026, designated for certified Small Local Business Enterprises with a 5% bid discount). The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) targets generic pharmaceuticals and OTC products through three authorized wholesalers with pricing weighted at 75% in evaluation. The Texas HHS RFI (HHS0017013, posted April 3, 2026) explores direct-to-manufacturer prescription programs as a preliminary market-intelligence mechanism. The Seminole County naloxone procurement (IFB60459723LAS, due July 26, 2023 — note the date discrepancy in the source) seeks 1,900 units annually with quarterly deliveries. The mismatch between the code's nominal antibiotic scope and the actual work being solicited suggests this code may not be the appropriate taxonomy reference for pharmaceutical procurement activity in these jurisdictions, or that tagging practices vary significantly.